Published in Neuron on June 01, 1993
GSK3 takes centre stage more than 20 years after its discovery. Biochem J (2001) 7.74
Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci U S A (1998) 6.13
Uses for JNK: the many and varied substrates of the c-Jun N-terminal kinases. Microbiol Mol Biol Rev (2006) 3.30
Seeding of normal Tau by pathological Tau conformers drives pathogenesis of Alzheimer-like tangles. J Biol Chem (2011) 2.86
Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. J Clin Invest (2004) 2.80
Identification of a novel microtubule binding and assembly domain in the developmentally regulated inter-repeat region of tau. J Cell Biol (1994) 2.61
Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proc Natl Acad Sci U S A (2004) 2.48
Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease. Proc Natl Acad Sci U S A (1994) 2.39
Chaperones increase association of tau protein with microtubules. Proc Natl Acad Sci U S A (2003) 2.32
Missense and silent tau gene mutations cause frontotemporal dementia with parkinsonism-chromosome 17 type, by affecting multiple alternative RNA splicing regulatory elements. Proc Natl Acad Sci U S A (1999) 2.26
Stu2p: A microtubule-binding protein that is an essential component of the yeast spindle pole body. J Cell Biol (1997) 2.14
Pathogenic implications of mutations in the tau gene in pallido-ponto-nigral degeneration and related neurodegenerative disorders linked to chromosome 17. Proc Natl Acad Sci U S A (1998) 2.13
The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nat Commun (2011) 2.00
High prevalence of mutations in the microtubule-associated protein tau in a population study of frontotemporal dementia in the Netherlands. Am J Hum Genet (1999) 1.87
Rho guanosine triphosphatase mediates the selective stabilization of microtubules induced by lysophosphatidic acid. J Cell Biol (1998) 1.85
Epitope mapping of monoclonal antibodies to the paired helical filaments of Alzheimer's disease: identification of phosphorylation sites in tau protein. Biochem J (1994) 1.85
Functional interactions between the proline-rich and repeat regions of tau enhance microtubule binding and assembly. Mol Biol Cell (1997) 1.81
Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform. EMBO J (1995) 1.77
Total and phosphorylated tau protein as biological markers of Alzheimer's disease. Exp Gerontol (2009) 1.75
Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5. Proc Natl Acad Sci U S A (2000) 1.73
Abnormal expression of the cell cycle regulators P16 and CDK4 in Alzheimer's disease. Am J Pathol (1997) 1.71
Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets. Cold Spring Harb Perspect Med (2011) 1.68
Mitotic and mitogenic Wnt signalling. EMBO J (2012) 1.62
Allostery in the Hsp70 chaperone proteins. Top Curr Chem (2013) 1.52
Allosteric drugs: the interaction of antitumor compound MKT-077 with human Hsp70 chaperones. J Mol Biol (2011) 1.49
Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome. FASEB J (2008) 1.43
Evidence that non-fibrillar tau causes pathology linked to neurodegeneration and behavioral impairments. J Alzheimers Dis (2008) 1.43
Impaired neurogenesis is an early event in the etiology of familial Alzheimer's disease in transgenic mice. J Neurosci Res (2010) 1.42
Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration. Biochem J (1997) 1.42
Nucleation-dependent tau filament formation: the importance of dimerization and an estimation of elementary rate constants. J Biol Chem (2008) 1.42
The endogenous and cell cycle-dependent phosphorylation of tau protein in living cells: implications for Alzheimer's disease. Mol Biol Cell (1998) 1.41
Distinct FTDP-17 missense mutations in tau produce tau aggregates and other pathological phenotypes in transfected CHO cells. Mol Biol Cell (2000) 1.39
Acetylated tau, a novel pathological signature in Alzheimer's disease and other tauopathies. Brain (2012) 1.38
Site-specific effects of tau phosphorylation on its microtubule assembly activity and self-aggregation. Eur J Neurosci (2007) 1.36
Correlation between caspase activation and neurofibrillary tangle formation in Alzheimer's disease. Am J Pathol (2001) 1.35
The cytoskeleton in neurodegenerative diseases. J Pathol (2004) 1.35
Identification of aminothienopyridazine inhibitors of tau assembly by quantitative high-throughput screening. Biochemistry (2009) 1.28
Age-dependent induction of congophilic neurofibrillary tau inclusions in tau transgenic mice. Am J Pathol (2001) 1.28
Mutations in tau gene exon 10 associated with FTDP-17 alter the activity of an exonic splicing enhancer to interact with Tra2 beta. J Biol Chem (2003) 1.22
Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients : an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay. Am J Pathol (2002) 1.22
Efficacy of small-molecule glycogen synthase kinase-3 inhibitors in the postnatal rat model of tau hyperphosphorylation. Br J Pharmacol (2007) 1.21
Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies. Philos Trans R Soc Lond B Biol Sci (1999) 1.21
Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine. Acta Neuropathol (2014) 1.21
The characterization of microtubule-stabilizing drugs as possible therapeutic agents for Alzheimer's disease and related tauopathies. Pharmacol Res (2010) 1.20
SOD1 (copper/zinc superoxide dismutase) deficiency drives amyloid β protein oligomerization and memory loss in mouse model of Alzheimer disease. J Biol Chem (2011) 1.19
The development of cell processes induced by tau protein requires phosphorylation of serine 262 and 356 in the repeat domain and is inhibited by phosphorylation in the proline-rich domains. Mol Biol Cell (1999) 1.17
Transgenic expression of the shortest human tau affects its compartmentalization and its phosphorylation as in the pretangle stage of Alzheimer's disease. Am J Pathol (1999) 1.17
Overexpression of the human NFM subunit in transgenic mice modifies the level of endogenous NFL and the phosphorylation state of NFH subunits. J Cell Biol (1995) 1.17
Anesthesia-induced hyperphosphorylation detaches 3-repeat tau from microtubules without affecting their stability in vivo. J Neurosci (2008) 1.15
The excitotoxin quinolinic acid induces tau phosphorylation in human neurons. PLoS One (2009) 1.15
β-Amyloid impairs axonal BDNF retrograde trafficking. Neurobiol Aging (2009) 1.13
Tau-based treatment strategies in neurodegenerative diseases. Neurotherapeutics (2008) 1.13
Paired helical filament tau in Alzheimer's disease. The kinase connection. Am J Pathol (1994) 1.12
Prominent axonopathy and disruption of axonal transport in transgenic mice expressing human apolipoprotein E4 in neurons of brain and spinal cord. Am J Pathol (2000) 1.11
Cell cycle-dependent phosphorylation and microtubule binding of tau protein stably transfected into Chinese hamster ovary cells. Mol Biol Cell (1995) 1.10
Secreted beta-amyloid precursor protein stimulates mitogen-activated protein kinase and enhances tau phosphorylation. Proc Natl Acad Sci U S A (1994) 1.09
Tau-directed drug discovery for Alzheimer's disease and related tauopathies: a focus on tau assembly inhibitors. Exp Neurol (2009) 1.08
The Role of p38 MAPK and Its Substrates in Neuronal Plasticity and Neurodegenerative Disease. J Signal Transduct (2012) 1.08
Human tau becomes phosphorylated and forms filamentous deposits when overexpressed in lamprey central neurons in situ. Proc Natl Acad Sci U S A (1997) 1.05
Are tangles as toxic as they look? J Mol Neurosci (2011) 1.05
Tau and tauopathies. Prog Mol Biol Transl Sci (2012) 1.04
Cleavage and conformational changes of tau protein follow phosphorylation during Alzheimer's disease. Int J Exp Pathol (2008) 1.04
Tau protein is phosphorylated by cyclic AMP-dependent protein kinase and calcium/calmodulin-dependent protein kinase II within its microtubule-binding domains at Ser-262 and Ser-356. Biochem J (1996) 1.04
Formation and propagation of tau oligomeric seeds. Front Neurol (2013) 1.04
Tau oligomers impair artificial membrane integrity and cellular viability. J Biol Chem (2012) 1.03
The role of cell cycle-mediated events in Alzheimer's disease. Int J Exp Pathol (1999) 1.02
Inhibition of JNK by a peptide inhibitor reduces traumatic brain injury-induced tauopathy in transgenic mice. J Neuropathol Exp Neurol (2012) 1.02
Tau phosphorylation affects its axonal transport and degradation. Neurobiol Aging (2013) 1.00
Alzheimer's disease and anesthesia. Front Neurosci (2011) 1.00
Kinesin-1 transport reductions enhance human tau hyperphosphorylation, aggregation and neurodegeneration in animal models of tauopathies. Hum Mol Genet (2010) 1.00
Nitration of tau protein is linked to neurodegeneration in tauopathies. Am J Pathol (2003) 1.00
Stable expression in Chinese hamster ovary cells of mutated tau genes causing frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). Am J Pathol (1999) 0.99
Chemical and immunological heterogeneity of fibrillar amyloid in plaques of Alzheimer's disease and Down's syndrome brains revealed by confocal microscopy. Am J Pathol (1995) 0.97
Potency of a tau fibrillization inhibitor is influenced by its aggregation state. Arch Biochem Biophys (2007) 0.97
Regulation of phosphorylation of tau by cyclin-dependent kinase 5 and glycogen synthase kinase-3 at substrate level. FEBS Lett (2006) 0.97
GSK-3 in Neurodegenerative Diseases. Int J Alzheimers Dis (2011) 0.97
Tau potentiates nerve growth factor-induced mitogen-activated protein kinase signaling and neurite initiation without a requirement for microtubule binding. J Biol Chem (2010) 0.96
Tangles, Toxicity, and Tau Secretion in AD - New Approaches to a Vexing Problem. Front Neurol (2013) 0.96
Dysregulation of protein phosphorylation/dephosphorylation in Alzheimer's disease: a therapeutic target. J Biomed Biotechnol (2006) 0.96
Familial FTDP-17 missense mutations inhibit microtubule assembly-promoting activity of tau by increasing phosphorylation at Ser202 in vitro. J Biol Chem (2009) 0.96
Pathogenic missense MAPT mutations differentially modulate tau aggregation propensity at nucleation and extension steps. J Neurochem (2008) 0.96
Knockout of plasminogen activator inhibitor 1 gene reduces amyloid beta peptide burden in a mouse model of Alzheimer's disease. Neurobiol Aging (2009) 0.95
Proteolytic cleavage of apolipoprotein E4 as the keystone for the heightened risk associated with Alzheimer's disease. Int J Mol Sci (2013) 0.95
Microtubule-stabilizing agents as potential therapeutics for neurodegenerative disease. Bioorg Med Chem (2013) 0.94
Staging of neurofibrillary degeneration caused by human tau overexpression in a unique cellular model of human tauopathy. Am J Pathol (2001) 0.94
Calpain-mediated tau cleavage: a mechanism leading to neurodegeneration shared by multiple tauopathies. Mol Med (2011) 0.93
The phosphorylation state of the microtubule-associated protein tau as affected by glutamate, colchicine and beta-amyloid in primary rat cortical neuronal cultures. Biochem J (1995) 0.93
Death-associated protein kinase 1 has a critical role in aberrant tau protein regulation and function. Cell Death Dis (2014) 0.93
Lysine methylation is an endogenous post-translational modification of tau protein in human brain and a modulator of aggregation propensity. Biochem J (2014) 0.93
Dysregulation of tau phosphorylation in mouse brain during excitotoxic damage. J Alzheimers Dis (2009) 0.92
HDAC6 mutations rescue human tau-induced microtubule defects in Drosophila. Proc Natl Acad Sci U S A (2013) 0.92
The tauopathies: toward an experimental animal model. Am J Pathol (1999) 0.91
The physiological link between metabolic rate depression and tau phosphorylation in mammalian hibernation. PLoS One (2011) 0.91
Monoclonal antibodies to a 100-kd protein reveal abundant A beta-negative plaques throughout gray matter of Alzheimer's disease brains. Am J Pathol (1997) 0.91
The triggering receptor expressed on myeloid cells 2: "TREM-ming" the inflammatory component associated with Alzheimer's disease. Oxid Med Cell Longev (2013) 0.89
Glutamate metabolism is impaired in transgenic mice with tau hyperphosphorylation. J Cereb Blood Flow Metab (2013) 0.89
PTEN, a widely known negative regulator of insulin/PI3K signaling, positively regulates neuronal insulin resistance. Mol Biol Cell (2012) 0.89
The interrelationship of proteasome impairment and oligomeric intermediates in neurodegeneration. Aging Cell (2015) 0.89
Brain-penetrant microtubule-stabilizing compounds as potential therapeutic agents for tauopathies. Biochem Soc Trans (2012) 0.88
A noncatalytic domain of glycogen synthase kinase-3 (GSK-3) is essential for activity. J Biol Chem (2010) 0.87
Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology (2005) 21.67
Alpha-synuclein in Lewy bodies. Nature (1997) 20.83
Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. Arch Neurol (2001) 9.96
Neurodegenerative tauopathies. Annu Rev Neurosci (2001) 9.53
Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med (2001) 9.51
alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc Natl Acad Sci U S A (1998) 8.41
Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron (1989) 8.04
Second consensus statement on the diagnosis of multiple system atrophy. Neurology (2008) 7.27
Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology (2009) 7.04
Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci U S A (1998) 6.13
Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol (1997) 6.12
Comparing predictors of conversion and decline in mild cognitive impairment. Neurology (2010) 5.69
Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science (2000) 5.62
A68: a major subunit of paired helical filaments and derivatized forms of normal Tau. Science (1991) 5.60
Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol (1998) 5.47
Paradoxical activation of Raf by a novel Raf inhibitor. Chem Biol (1999) 4.98
MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers. Brain (2009) 4.51
Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer disease. Proc Natl Acad Sci U S A (1988) 4.45
Relationships between biomarkers in aging and dementia. Neurology (2009) 4.16
Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans. Nature (1996) 4.12
Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease. Ann Neurol (1996) 4.10
Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science (1998) 4.07
A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J Biol Chem (2000) 3.97
Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J Neurosci (2000) 3.90
Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. Proc Natl Acad Sci U S A (2000) 3.86
Cingulin, a new peripheral component of tight junctions. Nature (1988) 3.81
Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron (1997) 3.73
MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology (2009) 3.72
Identification of two distinct synucleins from human brain. FEBS Lett (1994) 3.61
Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron (1999) 3.49
Expression of separate isoforms of human tau protein: correlation with the tau pattern in brain and effects on tubulin polymerization. EMBO J (1990) 3.36
Epitopes that span the tau molecule are shared with paired helical filaments. Neuron (1988) 3.28
Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci Lett (1998) 3.26
Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404. J Neurosci Res (1994) 3.26
Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205. Neurosci Lett (1995) 3.15
The switch of tau protein to an Alzheimer-like state includes the phosphorylation of two serine-proline motifs upstream of the microtubule binding region. EMBO J (1992) 3.04
Activation of the Wnt signaling pathway: a molecular mechanism for lithium action. Dev Biol (1997) 3.03
Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci (2001) 2.89
DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology (2007) 2.86
MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. Neurology (2009) 2.83
Local modulation of neurofilament phosphorylation, axonal caliber, and slow axonal transport by myelinating Schwann cells. Cell (1992) 2.80
The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging. Exp Neurol (1999) 2.73
Conversion of SB 203580-insensitive MAP kinase family members to drug-sensitive forms by a single amino-acid substitution. Chem Biol (1998) 2.73
The human mid-size neurofilament subunit: a repeated protein sequence and the relationship of its gene to the intermediate filament gene family. EMBO J (1987) 2.72
CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease. Neurology (2010) 2.67
Glucocerebrosidase mutations are an important risk factor for Lewy body disorders. Neurology (2006) 2.65
Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology (2011) 2.61
Genetic evidence for the involvement of tau in progressive supranuclear palsy. Ann Neurol (1997) 2.60
The mas oncogene encodes an angiotensin receptor. Nature (1988) 2.53
Pure, postmitotic, polarized human neurons derived from NTera 2 cells provide a system for expressing exogenous proteins in terminally differentiated neurons. J Neurosci (1992) 2.50
Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. Ann Neurol (1998) 2.47
Myelin-associated glycoprotein is a myelin signal that modulates the caliber of myelinated axons. J Neurosci (1998) 2.43
Maturation and endosomal targeting of beta-site amyloid precursor protein-cleaving enzyme. The Alzheimer's disease beta-secretase. J Biol Chem (2000) 2.42
Tau protein pathology in neurodegenerative diseases. Trends Neurosci (1998) 2.37
Synucleinopathies: clinical and pathological implications. Arch Neurol (2001) 2.36
Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation. J Biol Chem (1998) 2.32
Nestin expression in embryonic human neuroepithelium and in human neuroepithelial tumor cells. Lab Invest (1992) 2.30
Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein. Proc Natl Acad Sci U S A (1999) 2.30
Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology (2000) 2.27
Missense and silent tau gene mutations cause frontotemporal dementia with parkinsonism-chromosome 17 type, by affecting multiple alternative RNA splicing regulatory elements. Proc Natl Acad Sci U S A (1999) 2.26
Tau proteins with FTDP-17 mutations have a reduced ability to promote microtubule assembly. FEBS Lett (1998) 2.26
Clinical and neuropathologic variation in neuronal intermediate filament inclusion disease. Neurology (2004) 2.23
Serial MRI and CSF biomarkers in normal aging, MCI, and AD. Neurology (2010) 2.20
Active site titration and aminoacyl adenylate binding stoichiometry of aminoacyl-tRNA synthetases. Biochemistry (1975) 2.18
Induction of alpha-synuclein aggregation by intracellular nitrative insult. J Neurosci (2001) 2.16
Alzheimer's A beta(1-42) is generated in the endoplasmic reticulum/intermediate compartment of NT2N cells. Nat Med (1997) 2.15
Two-stage expression of neurofilament polypeptides during rat neurogenesis with early establishment of adult phosphorylation patterns. J Neurosci (1987) 2.15
Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro. J Biol Chem (1999) 2.13
Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer's disease paired helical filament tau. Neuron (1994) 2.13